Volatile anesthetics and liver injury: A clinical update or what every anesthesiologist should know
The use of any anesthetic agent must be based on specific knowledge of its benefits and risks, how it may produce toxicity and in which patients it may be most safely administered. Clearly, the perfect anesthetic agent does not yet exist and individual patient circumstances will continue to dictate the choice and use of inhaled anesthetics in clinical practice. Reports such as that by Tungea et al. remind us of the need for continued vigilance. As ongoing research attempts to uncover emerging toxicities, the clinician is challenged to balance new information with current clinical practices and choose the safest, most effective agents for each patient.
KeywordsHalothane Sevoflurane Anesthetic Agent Enflurane Hepatic Injury
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Tung D, Yoshida EM, Wang CS, Steinbrecher UP.
Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anesth 2005; 52: 133–6.PubMedCrossRefGoogle Scholar
Njoku D, Laster MJ, Gong DH, et al.
Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997; 84: 173–8.PubMedCrossRefGoogle Scholar
Hoet P, Graf ML, Bourdi M, et al.
Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 1997; 350: 556–9.PubMedCrossRefGoogle Scholar
Harris JW, Pohl LR, Martin JL, Anders MW.
Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trichloroethane. Proc Natl Acad Sci USA 1991; 88: 1407–10.PubMedCrossRefGoogle Scholar
Sadove MS, Kim SI.
Hepatitis after use of two different fluorinated anesthetic agents. Anesth Analg 1974; 53: 336–40.CrossRefGoogle Scholar
Sigurdsson J, Hreidarsson AB, Thejodleifsson B.
Enflurane hepatitis. A report of a case with a previous history of halothane hepatitis. Acta Anaesthesiol Scand 1985; 29: 495–6.PubMedCrossRefGoogle Scholar
Christ DD, Kenna JG, Kammerer W, Satoh H, Pohl LR.
Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69: 833–8.PubMedCrossRefGoogle Scholar
Martin JL, Kenna JG, Pohl LR.
Antibody assays for the detection of patients sensitized to halothane. Anesth Analg 1990; 70: 154–9.PubMedCrossRefGoogle Scholar
Martin JL, Keegan MT, Vasdev GM, et al.
Fatal hepatitis associated with isoflurane exposure and CYP2A6 autoantibodies. Anesthesiology 2001; 95: 551–3.PubMedCrossRefGoogle Scholar
Cousins MJ, Plummer JL, Hall PD.
Risk factors for halothane hepatitis. Aust N Z Surg 1989; 59: 5–14.CrossRefGoogle Scholar
Njoku DB, Greenberg RS, Bourdi M, et al.
Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 2002; 94: 243–9.PubMedCrossRefGoogle Scholar
Cullen SC, Gross EG.
The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951; 113: 580–2.PubMedCrossRefGoogle Scholar
Lachmann B, Armbruster S, Schairer W, et al.
Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990; 335: 1413–5.PubMedCrossRefGoogle Scholar
Luttropp HH, Thomasson R, Dahm S, Persson J, Wernfr O.
Clinical experience with minimal xenon anesthesia. Acta Anaesthesiol Scand 1994; 38: 121–5.PubMedCrossRefGoogle Scholar
Rossaint R, Reyle-Hahn M, Schulte Am Esch J, et al.
Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology 2003; 98: 6–13.PubMedCrossRefGoogle Scholar
© Canadian Anesthesiologists 2005